Truncated Syngap1 AAV Gene Therapy for Brain Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for SYNGAP1-associated neurodevelopmental disorders face challenges due to the large size of the full-length SYNGAP1 transcript and polypeptide, and difficulties in brain penetration, with no effective treatment available for conditions like SYNGAP1-related intellectual disability (SRID).
Innovation Solution
Development of viral vectors, particularly adeno-associated viral (AAV) vectors, that include nucleic acid encoding a truncated Syngap1 polypeptide, such as Syngap1-B:α1, to increase Syngap1 polypeptide levels in neurons, using optimized ITRs and UTRs for efficient expression and neuron-specific promoters for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If full-length SYNGAP1 transcript is used for gene therapy, then complete functional protein can be produced, but the large size prevents effective brain penetration and vector packaging
Solution Approach 1:
The SYNGAP1 gene is divided into multiple cassettes representing different exons (e.g., exons 1-7, 8-14, 15-20). These segmented cassettes can be individually packaged in AAV vectors and subsequently integrated into the genome to reconstruct the full-length functional SYNGAP1 protein, resolving the contradiction between functional completeness and vector size constraints
Solution Approach 2:
The patent transitions from attempting to deliver the entire SYNGAP1 transcript in a single vector to a multi-step process where segmented cassettes are delivered separately and then assembled in the target cells. This dimensional shift from monolithic delivery to distributed assembly enables brain penetration while maintaining functional completeness
2Ease of operation
If standard AAV vectors are used, then brain penetration is limited, but larger or modified vectors face manufacturing and delivery challenges
Solution Approach 1:
The complex task of delivering large SYNGAP1 sequences is segmented into multiple manageable AAV cassettes that can be manufactured and administered separately. Each cassette is within standard AAV packaging limits, simplifying manufacturing while achieving the ultimate goal of full-length protein expression through in vivo assembly
Solution Approach 2:
The patent performs preliminary segmentation and optimization of SYNGAP1 cassettes before delivery, designing each cassette with appropriate regulatory elements and ensuring compatibility for subsequent genomic integration. This preliminary preparation simplifies the actual delivery process and reduces complexity during administration
Data Source
AI summary
This document provides methods and materials for treating SYNGAP1-associated neurodevelopmental disorders (NDDs; e.g., SYNGAP1-related intellectual disability (SRID)). For example, viral vectors (e.g., adeno-associated viral (AAV) vectors) that include (e.g., are designed to include) nucleic acid encoding a truncated Syngap1 polypeptide (e.g., Syngap1-B:α1 polypeptide) are provided. In some cases, one or more viral vectors provided herein (e.g., AAV vectors that include nucleic acid encoding a truncated Syngap1 polypeptide such as a Syngap1-B:α1 polypeptide) can be administered to a mammal (e.g., a human) having, or at risk for developing, a SYNGAP1-associated NDD (e.g., SRID) to treat the mammal.